Prévention et traitement des infections
Author:
Klastersky J.,Aoun M.
Reference33 articles.
1. Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1: 23–35
2. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systemic review. J Clin Oncol 25: 3158–3167
3. Aapro MS, Cameron DA, Pettengell R et al. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy induced febrile neutropenia in adult patients with lymphomas and solid tumors. Europ J Cancer 42: 2433–2453
4. Leibovici L, Pau M, Cullen M et al. (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107: 1743–1751
5. Klastersky J, Paesmans M, Rubinstein ER et al. (2000) The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038–3051